Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
Please note that the ANZCTR website will be unavailable from 9am until 12:30pm (AEDT) on Tuesday 17th November for website maintenance.
Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT06910657
Registration number
NCT06910657
Ethics application status
Date submitted
21/03/2025
Date registered
4/04/2025
Date last updated
5/08/2026
Titles & IDs
Public title
IDOV-Immune for Advanced Solid Tumors
Query!
Scientific title
A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors
Query!
Additional trial identifiers [1]
0
0
VM-002-101
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Related trial records
Query!
Health condition
Health condition(s) studied:
Colorectal Cancer
0
0
Query!
Pancreatic Cancer
0
0
Query!
Melanoma
0
0
Query!
Ovarian Cancer
0
0
Query!
Gastric Cancer
0
0
Query!
Esophageal Cancer
0
0
Query!
Hepatocellular Carcinoma
0
0
Query!
Renal Cell Carcinoma
0
0
Query!
Breast Cancer
0
0
Query!
Sarcoma
0
0
Query!
Bladder Cancer
0
0
Query!
Lung Cancer
0
0
Query!
Prostate Cancer
0
0
Query!
Cervical Cancers
0
0
Query!
Head and Neck Cancers
0
0
Query!
Adrenal Gland Tumors
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Bowel - Back passage (rectum) or large bowel (colon)
Query!
Cancer
0
0
0
0
Query!
Pancreatic
Query!
Cancer
0
0
0
0
Query!
Malignant melanoma
Query!
Cancer
0
0
0
0
Query!
Ovarian and primary peritoneal
Query!
Cancer
0
0
0
0
Query!
Stomach
Query!
Cancer
0
0
0
0
Query!
Oesophageal (gullet)
Query!
Cancer
0
0
0
0
Query!
Liver
Query!
Cancer
0
0
0
0
Query!
Kidney
Query!
Cancer
0
0
0
0
Query!
Breast
Query!
Cancer
0
0
0
0
Query!
Sarcoma (also see 'Bone') - soft tissue
Query!
Cancer
0
0
0
0
Query!
Bone
Query!
Cancer
0
0
0
0
Query!
Bladder - transitional cell cancer
Query!
Cancer
0
0
0
0
Query!
Lung - Mesothelioma
Query!
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Cancer
0
0
0
0
Query!
Lung - Small cell
Query!
Cancer
0
0
0
0
Query!
Prostate
Query!
Cancer
0
0
0
0
Query!
Womb (Uterine or endometrial cancer)
Query!
Cancer
0
0
0
0
Query!
Cervical (cervix)
Query!
Cancer
0
0
0
0
Query!
Head and neck
Query!
Metabolic and Endocrine
0
0
0
0
Query!
Other endocrine disorders
Query!
Cancer
0
0
0
0
Query!
Other cancer types
Query!
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of the intervention or exposure
Treatment: Other - IDOV-Immune (oncolytic vaccinia virus)
Experimental: IDOV-Immune Dose Escalation Arm - Participants in this arm will receive a single intravenous (IV) infusion of IDOV-Immune, an investigational oncolytic vaccinia virus, on Day 1 of a 28-day treatment cycle. The study will follow a dose-escalation design, with each successive cohort receiving an increased dose based on safety data and observed dose-limiting toxicities (DLTs). Following dose escalation, expansion cohorts may be enrolled at selected dose levels to further assess safety and preliminary antitumor activity.
Treatment: Other: IDOV-Immune (oncolytic vaccinia virus)
IDOV-Immune is a genetically engineered oncolytic vaccinia virus designed to selectively infect and destroy tumor cells while stimulating the immune system. This study investigates IDOV-Immune as a single intravenous infusion in a first-in-human, Phase 1, dose-escalation trial in participants with advanced solid tumors. The dose will escalate based on safety data, with a goal of identifying the recommended Phase 2 dose (RP2D).
Query!
Intervention code [1]
0
0
Treatment: Other
Query!
Description of the comparator or control
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Incidence of Dose-Limiting Toxicities (DLTs)
Query!
Assessment method [1]
0
0
The number and proportion of participants experiencing dose-limiting toxicities (DLTs), assessed by dose level during the DLT evaluation period. DLTs are defined per protocol-specified criteria and graded according to CTCAE.
Query!
Timepoint [1]
0
0
From first dose through the end of the DLT evaluation period (28 days)
Query!
Primary outcome [2]
0
0
Safety and Tolerability of IDOV-Immune by Dose Level
Query!
Assessment method [2]
0
0
Incidence, severity, and relationship of treatment-emergent adverse events (TEAEs) by dose level.
Query!
Timepoint [2]
0
0
From first dose through end of treatment (28 days) (and/or safety follow-up period as defined in protocol [90 days])
Query!
Primary outcome [3]
0
0
Determination of the Maximum Tolerated Dose (MTD)
Query!
Assessment method [3]
0
0
Dose level(s) at which the observed incidence of dose-limiting toxicities meets protocol-defined criteria for maximum tolerated dose determination.
Query!
Timepoint [3]
0
0
From first dose through completion of dose-escalation cohorts (2 years)
Query!
Primary outcome [4]
0
0
Identification of Dose Level(s) for Further Clinical Evaluation
Query!
Assessment method [4]
0
0
Dose level(s) selected for further clinical evaluation based on integrated safety, tolerability, and pharmacokinetic data, as defined in the protocol.
Query!
Timepoint [4]
0
0
From first dose through completion of dose-escalation and data review (2 years)
Query!
Secondary outcome [1]
0
0
Pharmacokinetic Parameters of IDOV-Immune by Dose Level
Query!
Assessment method [1]
0
0
Pharmacokinetic parameters including, but not limited to, maximum observed concentration (Cmax), area under the concentration-time curve (AUC), time to maximum concentration (Tmax), and half-life (t½), summarized by dose level.
Query!
Timepoint [1]
0
0
From first dose through completion of PK sampling (2 years)
Query!
Secondary outcome [2]
0
0
Pharmacodynamic and Biomarker Responses Following IDOV-Immune Administration
Query!
Assessment method [2]
0
0
Changes in protocol-specified pharmacodynamic and exploratory biomarker endpoints over time, summarized by dose level.
Query!
Timepoint [2]
0
0
From first dose through completion of biomarker assessments (2 years)
Query!
Secondary outcome [3]
0
0
Objective Response Rate (ORR)
Query!
Assessment method [3]
0
0
Percentage of participants with a best overall response of complete response (CR) or partial response (PR), assessed per RECIST v1.1.
Query!
Timepoint [3]
0
0
Up to 12 months
Query!
Secondary outcome [4]
0
0
Duration of Response (DOR)
Query!
Assessment method [4]
0
0
Time from first documented objective response (CR or PR) to progression or death.
Query!
Timepoint [4]
0
0
Up to 12 months
Query!
Secondary outcome [5]
0
0
Disease Control Rate (DCR)
Query!
Assessment method [5]
0
0
Proportion of participants achieving CR, PR, or stable disease (SD) lasting at least 8 weeks.
Query!
Timepoint [5]
0
0
Up to 12 months
Query!
Secondary outcome [6]
0
0
Progression-Free Survival (PFS)
Query!
Assessment method [6]
0
0
Time from first dose to documented disease progression or death from any cause.
Query!
Timepoint [6]
0
0
Up to 12 months
Query!
Secondary outcome [7]
0
0
Overall Survival (OS)
Query!
Assessment method [7]
0
0
Time from first dose to death from any cause.
Query!
Timepoint [7]
0
0
Up to 12 months
Query!
Secondary outcome [8]
0
0
Incidence of Neutralizing Antibody Response
Query!
Assessment method [8]
0
0
Number of participants who develop detectable anti-vaccinia neutralizing antibodies after IDOV-Immune infusion.
Query!
Timepoint [8]
0
0
Up to 90 days post-treatment
Query!
Eligibility
Key inclusion criteria
Key
* Age = 18 years.
* Histologically or cytologically confirmed advanced solid tumors that have progressed despite standard therapy, or for which no standard therapy exists.
* ECOG performance status = 1.
* Measurable disease per RECIST v1.1.
* Adequate organ and bone marrow function.
* At least 28 days since major surgery, prior immunotherapy, or radiotherapy (with exceptions for minor procedures).
* Negative pregnancy test for women of childbearing potential.
* Agreement to use effective contraception during treatment and for 3 months after.
* Ability to provide informed consent and comply with study requirements.
Key
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Healthy volunteers
No
Query!
Key exclusion criteria
* Prior treatment with an oncolytic virus.
* Active or recent vaccinia virus infection or smallpox/monkeypox vaccination within 10 years.
* Active uncontrolled infection requiring systemic treatment.
* History of hepatitis B, hepatitis C, or HIV (unless meeting protocol-specific criteria).
* Unresolved = Grade 2 toxicities from prior therapies (except hair loss or stable chronic conditions).
* Active or symptomatic autoimmune disease requiring systemic therapy.
* Active or untreated CNS metastases (unless stable per protocol).
* Significant cardiac disease (e.g., NYHA Class III/IV heart failure).
* Interstitial lung disease or prior pneumonitis requiring steroids.
* Conditions requiring chronic immunosuppressive therapy.
* Severe skin disorders or history of pancreatitis.
* Bleeding disorders or history of recent serious thromboembolic events.
* Any medical or psychiatric condition that could interfere with study participation.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Not applicable
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
25/08/2025
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
31/05/2027
Query!
Actual
Query!
Sample size
Target
78
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
Westmead Hospital - Westmead
Query!
Recruitment hospital [2]
0
0
The Alfred Hospital - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [2]
0
0
3004 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Missouri
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Texas
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
ViroMissile, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight the tumor. The purpose of this study is to determine the safety of IDOV-Immune, how well it is tolerated, and to identify the highest dose that can be safely given. Researchers will also study how the drug behaves in the body, how the immune system responds to it, and whether it shows any signs of shrinking tumors. Participants will receive a single intravenous (IV) infusion of IDOV-Immune and will be closely monitored for side effects and any changes in their cancer. This study is being conducted at multiple sites in the United States and Australia.
Query!
Trial website
https://clinicaltrials.gov/study/NCT06910657
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Clinical Development
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
858-886-7718
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Undecided
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT06910657
Download to PDF